Intravenous Infusion Pumps Market To Reach $9.98 Billion By 2030

Intravenous Infusion Pumps Market Growth & Trends

The global intravenous infusion pumps market size is anticipated to reach USD 9.98 billion by 2030 and is anticipated to expand at a CAGR of 8.5% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic conditions, including cancer, diabetes, cardiovascular, and respiratory diseases, necessitates precise medication and therapy administration, thereby driving the demand for infusion pumps.

The global aging population further amplifies the adoption of infusion pumps, particularly in outpatient and home care settings, where they facilitate safe and accurate drug delivery for elderly patients managing complex medication regimens. The World Health Organization reported that life expectancy at birth increased to 73.3 years in 2024, a rise of 8.4 years since 1995. Moreover, the global population aged 60 and older is projected to reach 1.4 billion by 2030, up from 1.1 billion in 2023, highlighting the growing need for such technologies.

Technological advancements in infusion pump capabilities significantly bolster market demand. Smart infusion pumps, featuring wireless connectivity, EHR integration, and automated programming, enhance patient safety and operational efficiency by minimizing medication errors and streamlining workflows

 Request a free sample copy or view report summary: Intravenous Infusion Pump Market Report

Intravenous Infusion Pumps Report Highlights

• Volumetric infusion pumps held the largest market share in the product segment in 2024. Their efficacy in delivering large volumes precisely is vital in managing chronic diseases such as cancer and diabetes and in surgical procedures.

• Insulin infusion pumps are projected to grow at the fastest CAGR of over 9.0% over the forecast period. The global rise in diabetes prevalence, primarily due to aging populations, unhealthy lifestyles, and increasing obesity rates, has driven insulin pump demand.

• Pediatrics/neonatology dominated the disease indication segment with over 25.0% of the total revenue share in 2024.

• The chemotherapy segment is projected to grow at the fastest CAGR over the forecast period, driven by the rising number of cancer cases and rapid development in oncological drugs.

• North America dominated the intravenous infusion pumps market due to its advanced medical infrastructure, increasing chronic disease prevalence, and technological advancements.

• In May 2024, Moog Inc. received FDA 510(k) clearance for its CURLIN 8000 Ambulatory Infusion System. This new multi-therapy platform was designed for enhanced usability and safety in home infusion settings.

Intravenous Infusion Pump Market Segmentation

Grand View Research has segmented the global intravenous infusion pumps market on the basis of product, disease indication, and region:

Intravenous Infusion Pumps Product Outlook (Revenue, USD Million, 2018 - 2030)

• Volumetric infusion pumps

• Syringe infusion pumps

• Insulin infusion pumps

• Enteral infusion pumps

• Ambulatory infusion pumps

• Patient-controlled analgesia infusion pumps

• Implantable infusion pumps

• Others

Intravenous Infusion Pumps Disease Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Diabetes

• Gastroenterology

• Analgesia/Pain management

• Pediatrics/Neonatology

• Hematology

• Others

Intravenous Infusion Pumps Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Intravenous Infusion Pumps Market

• Baxter

• B. Braun Medical Inc.

• Medtronic

• Micrel Medical Devices SA

• Boston Scientific Corporation

• Cardinal Health

• Fresenius Kabi AG

• ICU Medical, Inc.

• F. Hoffmann-La Roche Ltd

• Tandem Diabetes Care, Inc.

• Terumo Corporation

• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

• Moog Inc.

• IRadimed Corporation